Comparison of the Results of Bronchoalveolar Lavage Culture and Endotracheal Aspirate Culture in Intubated Critically Ill COVID-19 Patients
NCT ID: NCT05403489
Last Updated: 2022-06-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
67 participants
OBSERVATIONAL
2021-01-01
2022-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Methods: We routinely apply BAL culture with bronchoscopy or ETA culture within the first 48 hours after intubating. We retrospectively screened cases who underwent BAL and ETA. They were divided into two groups: Group B and E. Evaluated parameters were compared in both groups.
Results: Demographic data and blood test results were similar in both groups. Intensive care unit (ICU) and intubation durations, and culture positivity were statistically significantly higher in Group B. Although not statistically significant, the mortality rate was higher in Group E. The most growth microorganisms were Candida species.
Conclusion: Mortality rates were consistent with the literature. Since the microorganism isolation rate is higher with BAL and antimicrobial treatment is applied more effectively; early deaths were prevented and stay periods were prolonged. In contrast, these durations were shorter in the ETA group due to higher mortality. In intubated COVID-19 cases, a more effective treatment process can be carried out by clearing the airway with fiberoptic bronchoscopy and by specifically planning the treatment according to the BAL culture. This may have a positive effect on prognosis and mortality.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Factors Affecting Mortality in Critical Patients Admitted to Intensive Care Unit Due to Coronavirus Disease 2019
NCT04659876
Clinical Characteristics, Outcomes and Risk Factors for Mortality in Pregnant/Puerperal Women With COVID-19 Admitted to ICU in Turkey: a Multicenter, Retrospective Study From a Middle-income Country.
NCT05930340
Risk Factors for Mortality for COVID-19 Admitted to an Intensive Care Unit
NCT04805645
Arterial and End-Tidal CO2 Gradient as a Mortality Predictor in Critical Care Patients
NCT05341258
Evaluation of the Fluid Response of SARS-CoV-2 (COVID-19) Patients in Intensive Care; Pleth Variability Index
NCT04373213
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group B (bronchoalveolar lavage)
Patients who underwent BAL\* were named Group B
\* BAL: bronchoalveolar lavage
Bronchoalveolar lavage
In cases approved for bronchoscopy, bronchoalveolar lavage was performed and culture analysis was performed.
Group E (endotracheal aspirate)
Patients who received ETA\*\* were named Group E.
\*\* ETA: Endotracheal aspirate
endotracheal aspirate culture
In cases where consent for bronchoscopy could not be obtained, tracheal secretions were aspirated and culture analysis was performed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bronchoalveolar lavage
In cases approved for bronchoscopy, bronchoalveolar lavage was performed and culture analysis was performed.
endotracheal aspirate culture
In cases where consent for bronchoscopy could not be obtained, tracheal secretions were aspirated and culture analysis was performed.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Above 18 years old patients
Exclusion Criteria
* Non intubated COVID-19 patients
* Below 18 years old patients
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Basri Cakiroglu
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Basri Cakiroglu
Hisar Intercontinental Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hasan Huseyin Kilic
Role: PRINCIPAL_INVESTIGATOR
Hisar Intercontinental Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hisar Intercontinental Hospital
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HisarIH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.